Ernexa Therapeutics Inc.
ERNA
$4.27
-$0.03-0.70%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -27.72% | 32.87% | 73.92% | 95.34% | 43.23% |
| Total Depreciation and Amortization | -20.00% | 24.64% | 1.47% | -84.48% | -90.48% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -70.09% | -58.40% | -27.49% | -101.73% | 117.38% |
| Change in Net Operating Assets | -6.29% | 290.61% | 96.50% | 108.51% | -126.31% |
| Cash from Operations | -63.98% | -9.64% | 67.62% | 79.76% | -12.08% |
| Capital Expenditure | -- | -- | -- | -15.79% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -15.79% | -- |
| Total Debt Issued | -- | -- | -- | -100.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.88% | 262,400.00% | -100.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.88% | 324.09% | -100.00% | -99.33% | 22,504.55% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -273.09% | 3,758.73% | 54.12% | 47.54% | 194.74% |